Pulsed electromagnetic field therapy in the management of knee OA

It seems most unusual that in a review of “all currently available treatments” for knee osteoarthritis (OA) by 21 authorities and “two experts in the field of guidelines methodology”, pulsed electromagnetic field therapy was not mentioned in the text or the 51 references.1 This is particularly troubling because over 2800 publications between 1966 and 1998 were retrieved. An identical search for efficacy of magnetic field therapy during this period listed 31 studies with at least one control group,2 including two double blind trials citing benefits in knee OA from a peer reviewed arthritis journal.3 In 1999 over 50 000 patients received pulsed signal therapy (PST) prescribed by over 1000 doctors at more than 300 clinics and hospitals in 16 countries, where it is usually reimbursed by fiscal intermediaries because of its proven record of cost effectiveness and safety. A summary of PST double blind and randomised study results in over 50 000 patients has been published,4 and findings in 100 000 patients (the vast majority with knee OA) have also been reported at recent international conferences.5 Although “alternative” remedies, ranging from minerals, vitamins, nutritional supplements, and capsicain and diclofenac gels to sex hormones were discussed, in contrast with PST, none satisfied the category criteria the panel established to determine strong recommendation. Nor do any have the solid basic science studies that PST provides with its in vitro support for mechanisms of action to explain efficacy based on proteoglycan synthesis and chondrocyte stimulation results.6

Pulsed signal therapy is the result of three decades of research designed to characterise the piezoelectric signal that normally stimulates the formation of bone in the extracellular matrix when bone is subjected to pressure. Although the transmission of this signal is impaired in OA, PST can reproduce this streaming potential in affected joints under no load, and the nine one-hour daily non-invasive treatments are devoid of any adverse side effects. Long term follow up confirms sustained pain relief, improved mobility, and a high safety profile as assessed by validated instruments (WOMAC, QoL, mobility, and a high safety profile as assessed by validated instruments (WOMAC, QoL, mobility, and a high safety profile as assessed by validated instruments (WOMAC, QoL).7 Markoll R. A double-blind trial of pulsed electromagnetic fields in osteoarthritis. J Rheumatol 1993;20:443–9.

Although I am certified in cardiology and gastroenterology, a significant portion of my practice is now devoted to exploring how PST achieves its benefits.8 I have treated 1000 patients, most of whom had knee OA, with very gratifying results similar to those reported in the literature. The panel cited two prior efforts to establish guidelines for treating knee OA, emphasising that these “primarily represent consensus statements from expert panels” and “there is no evidence of support that such guidelines remain unclear.” Their stated objective, therefore, was to “defuse guidelines relating to clinical issues in OA management, and to indicate clearly the levels of evidence to support individual statements”. However, electromagnetic therapy approaches were again omitted, though at least one of the members is quite familiar with PST. The reason for this exclusion is not clear and I believe that your readership deserves to be aware of this extremely safe and effective option.

K PFEIFFER
Augburgerstr 4, 80337 München, Germany


Authors’ reply

We thank Dr Pfeiffer for raising this point. The EULAR recommendations for the management of knee osteoarthritis1 combined an evidence based approach and a consensus approach. The evidence based approach—that is, the literature research, was only applied for the treatment modalities selected by the experts at the first meeting of the committee (see table 1 of the paper).

Pulsed electromagnetic field therapy, with other less commonly used interventions, was not included in this list, and its evidence for efficacy was therefore not assessed. However, as emphasised by Dr Pfeiffer, any evidence based evaluation of all other interventions would be of interest and could be considered for inclusion in the next round of evidence based guidelines.

M DOUGADOS
Clinique de Rhumatologie B, Groupe Hospitalier Cochin, 27 rue du Fauborg St Jacques, 75679 Paris CEDEX 14, France

M DOHERTY
Rheumatology Unit, City Hospital, Nottingham NG5 1PB, UK

Treatment of women with aPL in pregnancy

I read with much interest the article of Derksen et al in the January issue of the Annals of the Rheumatic Diseases.1 The authors gave a detailed introduction to the result of treatment of pregnant patients with antiphospholipid syndrome (APS). Despite the presence of only a limited amount of data from controlled studies the authors gave helpful recommendations for the daily management of these patients.

However, there is a major concern with which I would like to deal. As we know the success of treatment of APS with oral anticoagulants very much depends on the strictness with which the dose is adjusted to the international normalised ratio. The authors rightly suggest changing from oral anticoagulants to subcutaneous low molecular weight heparin in pregnant patients with APS. However, I believe that the dose of low molecular weight heparin has to be adjusted in individual patients.

The measurement of anti-factor Xa activity in plasma enables us to calculate the dose of low molecular weight heparin which is needed to achieve optimal inhibition of the coagulation cascade. Values of 0.6–1.0 U/ml are believed to give maximum protection against thromboembolic events.

From my experience the optimal dose of low molecular weight heparin may be different in different patients. Moreover, a given once daily rarely guarantees the desired value of anti-factor Xa activity and often a second injection has to be applied to achieve optimal effect. Therefore, as long as controlled data are missing I would recommend the measurement of anti-factor Xa activity in pregnant patients with APS should be used to adjust the dose of low molecular weight heparin. This may result in better protection of mother and fetus in this disease.

C PFEIFFER
Rheumatology Outpatient Unit, University Hospital of Heidelberg, Germany

christoph_fehm@med.uni-heidelberg.de

www.amrheumdis.com
Caudal epidural injections

Price et al recommend that caudal epidural injections should be carried out with x-ray screening.1 In practice the technique of

performed in the outpatient clinic, where screening facilities are not usually available.

I have reviewed the outcome of 44 unscreened caudal epidural injections given to 34 patients in my outpatient clinic in the 12 months from July 1999 to June 2000. Patient selection was largely on the basis of unilateral nerve root pain in the leg in the presence of symmetrical straight leg raising. However, nine patients had asymmetrically reduced straight leg raising and four of those with full straight leg raising had pain in the L4 dermatome, mostly with a positive femoral nerve stretch test on the affected side. Spinal mobility and the presence or absence of a neurological deficit did not influence the decision to offer an epidural injection.

The procedure was carried out with the patient lying prone on the examination couch. After thorough skin preparation and a local injection of 2 ml lidocaine (lignocaine) 2%, 40 mg triamcinolone hexacetonide mixed with 10 ml lidocaine 0.5% and 10 ml normal saline was injected into the epidural space through the sacral hiatus with a 20G spinal needle. The patient was subsequently kept prone for 30 minutes and remained horizontal for a total of 60 minutes before being allowed home.

Six of the patients were subsequently given a second epidural injection and two of them received three in the 12 month period. The procedure was repeated only if there was a satisfactory response to the original injection. For the purpose of this audit, outcomes were graded as:

1. Complete or substantial relief of root symptoms for a minimum of three months.
2. Temporary relief for between one week and three months.
3. A sustained partial response (up to 50% reduction in pain).
4. No response (negligible pain relief or pain reduced for less than one week).

After the first epidural injection, 13 patients were cured of their root pain or obtained relief for three months or more, six derived temporary relief, four partial relief, and 10 showed no response. One of the non-responders was subsequently deemed to have Achilles tendinitis rather than S1 root pain. The outcome in the remaining case is unknown as the patient defaulted from follow up.

Of the eight patients who received a second epidural injection, three were cured or had sustained relief, three had partial relief, and two did not respond (despite previous satisfactory responses for four and nine months, respectively). Of the two patients who were given a third epidural injection, one enjoyed sustained relief of pain while the other had temporary relief for six to eight weeks.

In brief, 23/34 (68%) of patients experienced at least a temporary or partial response to the initial unscreened caudal epidural injection and of the eight patients who were given a second or third epidural injection, four obtained sustained relief from their leg pain. There were no complications from the procedure.

On further analysis of the results, 68% of patients with full straight leg raising showed at least a temporary response to the first epidural injection compared with 44% of those with asymmetrically reduced straight leg raising. Of patients with neurological deficit, 85% experienced at least temporary pain relief.

Sixteen patients (47%) were ultimately referred to the chronic pain management services for nerve root blocks and three (9%) for a surgical opinion on the basis of the results of a magnetic resonance imaging scan of their lumbar spine.

Although x-ray guidance theoretically might improve the accuracy of placement of the spinal needle, these results show that caudal epidural injections can be carried out safely and effectively in an outpatient setting without radiological screening. This also ensures prompter treatment for the patient.

N J SHEEHAN
Department of Rheumatology, Edith Cavell Hospital, Breton Gate, Peterborough PE3 9GZ, UK

www.annrheumdis.com

Interleukin 1 gene polymorphisms

I read with interest the recent article by Grilly and colleagues1 on the potential use of interleukin 1 (IL1) gene polymorphisms in predicting the need for joint surgery in patients with rheumatoid arthritis. Although the authors’ findings are certainly encouraging and worthy of further investigation, I would like to raise a couple of points as to how these were arrived at in the first place.

When adopting the “candidate gene” approach in any disease association study, it pays to consider carefully the physiological context of a hypothesis. In this case the authors worked on the premise that one of the IL1 gene family polymorphisms investigated might correlate with disease outcome. This outcome included polymorphisms both in the IL1 genes and the IL1 receptor antagonist (IL1ra) locus. The IL1ra is unique in being the only known endogenous cytokine receptor antagonist. The genes encoding IL1α, β


Authors’ reply

We thank Dr Fiehn for his interest and comments on our recent leader in the Annals. At present, there are insufficient data from randomised trials to give evidence based guidelines for optimal (prophylactic) treatment of many of the clinical manifestations of the antiphospholipid syndrome (APS). This not only holds for prevention of pregnancy related complications, the topic of our leader, but also for treatment of thrombosis related to antiphospholipid antibodies.1

The major issue raised by Dr Fiehn is that he believes that in patients with APS one should use adjusted, not fixed, doses of low molecular weight heparin (LMWH). It is well known that anti-Xa activity relates to anti-thrombotic effects of LMWHs, and that the amount of LMWH needed to achieve and maintain a certain range of anti-Xa activity increases during the course of pregnancy. In most patients dose adjustment is needed in the second trimester and, in some, in the third trimester (mean (SD) 20.5 (8.2) weeks), but individual patients vary widely in the time when the dose of LMWH needs to be adjusted from once to twice daily.1 Despite this, there is no far clinical proof that for thrombophrophylaxis in pregnancy or prevention of poor pregnancy outcome an adjusted dose LMWH (with cumbersome and costly monthly monitoring of pre- and/or post-injection anti-Xa activity) is better than a fixed dose based on body weight.1,2 Therefore, we do not share Dr Fiehn’s view that one should advise adjusted doses of LMWH in all pregnant patients with APS.

R H W M DERKSEN
Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, The Netherlands

P G DE GROOT
Department of Haematology

H K NIEUWENHUIS
Department of Obstetrics and Gynaecology

G C M L CHRISTIAENS
Haemostasis and Thrombosis Laboratory


Authors’ reply

Dr Sheehan’s letter describes an audit of the efficacy of caudal epidural injections. His audit clearly describes outcomes of sciatica, that most patients will improve spontaneously with time alone. The degree of improvements in the audit is not dissimilar to that expected from the natural history of the condition. It is therefore difficult to state that the caudal epidural injections were as effective. Certainly it is not possible from this audit to state that screened epidural injections would not be more effective.

C PRICE
Pain Clinic, Royal South Hants Hospital, Southampton University Hospitals NHS Trust, Brinton’s Terrace, Southampton, Hampshire

1 Price et al recommend that caudal epidural injections should be carried out with x-ray screening.1 In practice the technique of
and the IL1ra have co-evolved as a cytokine control mechanism: agents eliciting IL1 production generally induce IL1ra gene transcription as well, either directly or through a feedback loop triggered by IL1 itself. IL1ra competes with IL1 for binding to the cognate receptor, but produces no known signalling events upon binding. Additionally, one of the two IL1 receptors, type II, also lacks any known signalling capacity and is thought to function as a decoy binding site. If it is assumed that polymorphisms found in members of the IL1 gene family modify gene function then the implication is that they should be studied collectively, not individually. In support of this argument comes recent experimental evidence showing that two IL1Ra receptors, type II, also lacks any polymorphisms associated with allelic combinations within the IL1 gene family, as well as evidence for linkage disequilibrium between polymorphic markers spread across the IL1 gene family locus. It is fair to say that Crilly and colleagues did allude in their paper to the possible existence of an extended IL1 gene family haplotype. However, there is already sufficient published evidence to justify examination of haplotypic combinations of the investigated alleles in population studies.

On a different note, although the authors’ argument about the validity of surgery as a study end point is convincing, their selection of 15 years as the cut off point for this study seems dubious. A previous study by the same group had calculated that the median disease duration before surgery was 14.6 years, implying that there are a substantial number of patients in the “no surgery” group who will require surgery shortly after the 15 year time point, thereby potentially confounding any significant statistical findings. One might argue that the aim of this study was not to differentiate between patients that will or will not require surgery but, rather, to differentiate between rapid (<15 years) versus delayed (>15 years to surgery) disease progression. Even so, a more valid statistical approach might have been to analyse all patients as a single group and try to correlate genotype (or haplotype) with disease duration to surgery.

J VAMVAKOPOULOS
University Department of Surgery, Addenbrooke’s Hospital, Cambridge, UK

Author’s reply

I thank Dr Vamvakopoulos for his interest in our article1 and would like to make the following response.

We agree that testing for haplotype combinations of the interleukin 1 (IL1) gene family allele would be useful. However, for a large number of alleles to be tested a considerable sample size would be needed to correct for multiple allele testing. This would require a multicentre study; this is limited by funding constraints.

Secondly, for the statistical analysis we predefined early and late surgery. Analysis was undertaken after discussion with a qualified medical statistician. Should the correspondents wish to analyse our data, we would be happy to allow access if guarantees can be provided.

R MADHOK
Centre for Rheumatic Diseases, Glasgow Royal Infirmary, 84 Castle Street, Glasgow G4 0SF, UK


LETTERS TO THE EDITOR

A case of shingles mimicking carpal tunnel syndrome

A 59 year old woman with an eight year history of seropositive erosive rheumatoid arthritis (RA) receiving sulfasalazine and penicillamine presented with severe sudden onset pain radiating from the left elbow to the left thumb at 73 mm/1st h. A transcutaneous nerve-stimulating (TENS) machine was applied and she was prescribed amitriptyline 25 mg at night. The following day she had improved significantly but had developed a vesicular rash in the C6 dermatome consistent with herpes zoster infection (fig 1). Viral titres were consistent with current varicella zoster infection.

DISCUSSION

Establishing the cause of pain in patients with RA can be notoriously difficult. In addition to the psychological factors that influence pain perception, wrist and hand pain may result from rheumatoid synovitis, soft tissue inflammation, or mechanical nerve compression at wrist, elbow, and cervical spine. Herpes zoster infection is heralded by burning discomfort in a dermatomal distribution, which may occur for up to five days before the onset of the typical rash. Cervical dermatomes are affected in up to 15% of patients2 and may result in diaphragmatic paralysis and lower motor neurone paresis.3 In this case the occurrence of prodromal symptoms of herpes zoster mimicked the symptoms of carpal tunnel syndrome, presumed secondary to RA synovitis.

RA increases the risk of herpes zoster infection.4 In one series the use of low dose methotrexate, long duration of disease, and seropositivity were risk factors for subsequent infection.5 Gold treatment may also increase the likelihood of shingles.6

Immunocompromised patients should receive acyclovir early to avoid viral dissemination. In patients with RA the complexity of the differential diagnosis may delay diagnosis unless the possibility of herpes zoster infection is kept in mind.

Conflict of interest: none.

H WILSON
J HAMILTON
R MADHOK
Centre for Rheumatic Diseases, University Department of Medicine, Glasgow Royal Infirmary, Glasgow G31 2ER, UK

Correspondence to: Dr H Wilson

References


Azathioprine hypersensitivity

Systemic hypersensitivity is a rare but documented side effect of azathioprine. The common adverse effects of azathioprine include...
fevers, gastrointestinal disturbances of nausea and vomiting, granulocytopenia, and hepato-cellular injury. More rarely, hypersensitivity can present with features of severe systemic infection and end organ dysfunction. Azathioprine is a commonly used immunosuppressive drug and is used in many medical specialties. Therefore recognizing azathioprine hypersensitivity is important for all doctors. We report a case in which we suspect such an azathioprine hypersensitivity reaction.

A 32 year old Asian woman with mixed connective tissue disorder presented with a one day history of general malaise, fevers, and painful digits. Fourteen days earlier treatment had been started with azathioprine 50 mg daily, and her prednisolone increased from 5 mg to 15 mg daily owing to the development of proteinuria (1.5 g on 24 hour urine collection) and urticarial vasculitis on her lower legs.

On examination she was shocked, with a blood pressure of 70/30 mm Hg and had marked acrocyanosis (fig 1). The differential diagnosis included a lupus crisis or sepsis. She was treated in the intensive care unit with intravenous ceftriaxone, metronidazole, and prophylaxis for digital ischaemia after serial cultures were taken from all major sites. Staphylococcal toxic shock was excluded, with no growth on vaginal swabs and a negative staphylococcal toxin test. After negative cultures 1 g methylprednisolone was given for a possible flare up of her connective tissue disease. The azathioprine was discontinued. She improved despite concomitant intravascular coagulation. Multiple cultures from all sites did not identify any source of sepsis.

We suspected azathioprine hypersensitivity owing to:

- The timing of the patient’s illness in relation to the initiation of azathioprine
- The presence of recognised features of hypersensitivity—fever, chills, diarrhoea, hypotension, and hepatic dysfunction
- The effect of rechallenge. Three weeks after the presenting episode, one dose of azathioprine 25 mg was given for steroid-sparing effect (the initial illness was attributed to disease flare up); the patient had a more severe and rapid hypersensitivity response requiring treatment with intravenous corticosteroids.

She improved after treatment with high dose corticosteroids. No cultures ever isolated an infective source.

This case shows the importance of recognising azathioprine hypersensitivity. Approximately 50 cases have been reported in patients with immune mediated diseases such as inflammatory bowel disease, multiple sclerosis, and immune thrombocytopenias, where the initial illness is often ascribed to sepsis or reactivation of underlying disease. Most reactions occur in the first four weeks of drug initiation. Hypersensitivity should always be included in the differential of fever, hypotension, and renal failure. The case was reported to the Committee on Safety of Medicines (United Kingdom).

The mechanism of the reaction is unclear. Azathioprine is composed of a nitroimidazole attached to 6-mercaptopurine. It is proposed that the imidazole component causes hypersensitivity, while the 6-mercaptopurine may cause haematological side effects. However, there are conflicting reports about the component of the drug to which the hypersensitivity reaction can be attributed. Fields reviewed 49 cases, where the reaction occurred equally in men and women, aged 16–76 years, and there was a wide variation in azathioprine doses. All patients who developed shock were also taking corticosteroids.

Support for an allergic reaction is that it occurs in only a small percentage of patients, and the event recurs with drug rechallenge, as occurred inadvertently in our patient. Rechallenge with azathioprine is therefore dangerous and should be done under careful observation. A hapten from the imidazole component may bind to a protein molecule to elicit type 1 hypersensitivity. Reactions mimicking sepsis may result from increased production of mediators such as tumour necrosis factor.


Figure 1 (A) A view of the patient’s feet three weeks after the initial presentation, showing demarcating digital ischaemia; (B) a close up view showing marked digital peripheral ischaemia.
Immunosuppressive treatment for vasculitis associated with Lyme borreliosis

Vasculitis of the central nervous system is a rare complication of Lyme borreliosis.\(^1\) We now report a case of early onset borrelia associated encephalitis followed by systemic vasculitis. Antibiotics failed to improve the clinical course and remission was only reached after extensive immunosuppressive treatment.

A 52 year old man was admitted because of fever, headache, tinnitus, and painful joints. He reported a tick bite on his left arm, which had occurred three weeks earlier and which was followed by a reddish skin eruption. His general practitioner started treatment with doxycycline, but the patient's condition worsened. The patient had a fever of 39.9°C, further physical examination showed no other abnormalities. Except for an erythrocyte sedimentation rate of 51 mm/1st h and a leucocyte count of 16.1×10\(^9\)/l, routine blood analysis was normal. Cultures (blood, urine, stool) were negative. Enzyme linked immunosorbent assays (ELISAs) showed an increased anti-borrelia-IgM titre of 322.5 EU/ml (normal <30) with normal IgG levels, suggestive of early stage Lyme borreliosis. This was supported by western immunoblotting, with reactivity towards anti-borrelia-IgM.

Shortly upon arrival at the ICU the patient was intubated and mechanically ventilated because of respiratory insufficiency due to muscle fatigue. Examination now disclosed numerous splinter haemorrhages distributed over the whole body. Ceftriaxone was continued for 10 days and then replaced by doxycycline. After 18 days antibiotic treatment was discontinued because of lack of improvement. Fever persisted and generalised epileptic seizures complicated the course. Cultures remained negative. An ELISA was repeated after four weeks: the anti-borrelia-IgM was then raised to 800 EU/ml; the IgG level was also above normal. The number of splinter haemorrhages increased and a non-oliguric renal insufficiency developed, resembling a glomerulonephritis with microsopic haematuria, granular casts, and proteinuria (0.9 g/24 h). Screening markers of autoimmune diseases (antineutrophil cytoplasmic antibodies, antinuclear antibodies, cryoglobulins) were negative. A skin-fascia-muscle biopsy sample taken from the right leg showed vasculitis of medium sized arteries (fig 1). No spirochaetes were detected in this sample. Treatment with prednisolone (1 mg/kg/day) did not improve the condition of the patient within one week, therefore, cyclophosphamide (2 mg/kg/day) was added. Within two days the patient regained normal neurological functions. Renal function improved within four weeks (serum creatinine decreasing from 249 to 130 µmol/l, blood urea nitrogen decreasing from 56.4 to 24.4 mmol/l of urea) and the patient was weaned from the ventilator. Follow up was uneventful.

Vasculitis may develop within weeks after infection and complicate the clinical course of Lyme borreliosis. To our knowledge, this is the first description of a systemic vasculitis including cerebral and renal disease after B. burgdorferi infection in a human being. Histological proof for vasculitis was assessed in a skin-fascia-muscle sample; the absence of spirochaetes therein suggests an autoimmune based pathogenesis.\(^1\) As in this case, laboratory support for acute B. burgdorferi infection is an important issue, especially in areas like the Netherlands.\(^1\) Whether elicited directly by the micro-organism or by secondary autoimmune mechanisms, vasculitis occurs in association with disseminated organ failure. Cyclophosphamide, successfully used in case of B. burgdorferi induced cerebral vasculitis,\(^1\) was effective for this case of systemic vasculitis as well.

In conclusion, persisting vasculitic activity should be suspected whenever antibiotic treatment does not improve the clinical course in Lyme borreliosis. When borrelia associated vasculitis has been histologically established, and does not respond to corticosteroid treatment alone, we suggest the combined use of prednisolone and cyclophosphamide.

R KOMDEUR
J G ZIJLSTRA
T S VAN DER WERF
J M LIGTENBERG
J E TULLEKEN

Department of Internal Medicine, Intensive and Respiratory Care Unit (ICB), University Hospital Groningen, The Netherlands

Correspondence to: Dr J E Tulleken, Intensive and Respiratory Care Unit (ICB), Department of Internal Medicine, University Hospital Groningen, PO 30.001, 9700 RB Groningen, The Netherlands e.tulleken@int.azg.nl

Figure 1 Skin-fascia-muscle biopsy sample showing vasculitis of a medium sized artery and some necrosis of the vessel wall.

Bilateral transient osteoporosis of the knee in pregnancy

Transient osteoporosis of pregnancy involving the hips has been reported widely. The knee is much less commonly affected and only isolated cases have been reported. We report the case of a woman in the third trimester of pregnancy with bilateral transient osteoporosis of the knees.

2 Sigal LH. Immunologic mechanisms in Lyme neuroborreliosis: the potential role of autologous and molecular mimicry. Semin Neurol 1997;17:63–8
A 36 year old woman presented with a one month history of pain in the left knee followed a week later by pain in the right. The right knee deteriorated over one to two weeks until she was unable to weight bear. There was no pain at rest. At the time of presentation she was 30 weeks pregnant with her first child conceived through in vitro fer-

A diagnosis of transient osteoporosis of pregnancy was entertained and the patient was treated with simple analgesics and followed up closely throughout the remainder of her pregnancy. She presented to the deliver-

Figure 1 Magnetic resonance imaging at presentation. The T1 weighted sagittal image of the right knee shows diffuse low signal in the posterior aspect of the lateral femoral condyle. Note the low signal fluid in the knee joint cavity.

of the disease. Two weeks post partum the pain had begun to resolve and she could walk without any aids. At three months post partum there was only residual discomfort in the right knee walking up and down stairs. Repeat MRI of the knees showed dramatic improvement in the bone marrow oedema. In the right knee there was only minor patchy oedema in the distal femur and proximal tibia. In the left knee there was some residual spotty marrow inhomogeneity in the lateral tibial plateau.

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-

Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinae-
ACHA levels in patients with various atherosclerotic vascular disorders. In this study ACHA levels of patients with SLE were compared with those of healthy donors.

Sixty eight patients (64 women, four men), aged 39.4 (10.6) (mean (SD)) years, who fulfilled at least four of the diagnostic criteria established by the American Rheumatism Association for SLE and 60 healthy donors (55 women, five men), aged 42.6 (8.12), were enrolled into the study. The SLEDAI (SLE Disease Activity Index) score was used to measure disease activity. Patients were considered to have active lupus if they scored at least 2 on the modified SLEDAI scale (calculated by omitting anti-dsDNA and complement). In order to evaluate the relationship between ACHA levels and disease manifestations, patients were considered to have active lupus if they scored at least 12 on the modified SLEDAI score.

The level of cholesterol-specific antibodies was measured by a solid phase enzyme immunoassay described earlier. Polyethylene plates (Greiner, Frickenhausen, Germany) were coated with 5 µg/well cholesterol dissolved in 100 µl absolute ethanol and incubated at 4°C for 24 hours. After washing with PBS, the plates were incubated with 100 µl PBS containing 0.1% casein. The binding of ACHA was detected by anti-human horseradish peroxidase conjugated γ-chain-specific rabbit antibodies (DAKO, Glostrup, Denmark), and with o-phenylene diamine (Sigma, St Louis, USA) using H2O2 as substrate. Optical density was measured at 492 nm (reference at 620 nm), and the mean of duplicates was calculated. Serial dilutions of purified immunoglobulin were used as standards in all experiments. Data obtained as optical density values were expressed in arbitrary units per millilitre (AU/ml), related to the standard curve. Our previous observations, in accordance with those of others, demonstrated the specificity of ACHA to cholesterol. The inter- and intra-assay variations of this method were 18.7% and 9.5%, respectively.

Differences between the parameters measured in controls and patients with SLE, between patients with active and inactive SLE, and between those patients with and without previous vascular events were calculated using the Mann-Whitney test. The χ² test was used to estimate the discriminative power of ACHA between patients with SLE and healthy donors. The correlation of individual parameters with each other and healthy donors. The correlation of individual parameters with each other and healthy donors was calculated using Spearman’s rank correlation test.

Twelve samples (18%) were considered as having been obtained from patients with active SLE and 56/68 (82%) from patients with inactive disease. Three of the 12 “active” samples were from patients with SLE active in more than one organ system and nine were from patients with disease activity in one organ system only (musculoskeletal (four), central nervous system (two), renal (two), and cutaneous (one)).

The difference between ACHA levels measured in the control group and in patients with SLE was significant (p<0.001) (fig 1). High ACHA levels were observed in the upper quartile occurred in 29/68 (43%) patients with SLE and 13/60 (22%) controls (p=0.012). ACHA levels (mean (SD)) of patients with active (97 (81) AU/ml) or inactive (64 (38) AU/ml) SLE did not differ significantly (p=0.21) and did not correlate with the SLEDAI score (r=0.22, p=0.066). No correlation was found between the ACHA levels and other parameters (such as anti-dsDNA, CH50, C3, and C4, data not shown). No significant differences were found between patients treated with corticosteroids for inactive disease or those with inactive disease and not receiving corticosteroid treatment (p=0.174). The latter group had not received corticosteroids for at least one year before blood samples were obtained. The difference between the ACHA levels of patients who had or had not experienced vascular events was not significant.

The observed increases of ACHA levels may be related to underlying chronic inflammatory disease. A number of conditions such as dyslipoproteinaemia, nephrotic syndrome, and changes in cholesterol membrane domains might have elicited the increase of ACHA levels. Corticosteroid treatment might also have stimulated ACHA production, though according to our observations this intervention does not alter ACHA levels significantly. A preventive role against atherosclerosis in patients with SLE has been attributed to raised ACHA levels, though these may also exert an atherogenic effect. Further studies are necessary to clarify the role of ACHA in the changes of lipid metabolism ascertained in patients with SLE.

This work was supported by grants OTKA No T 029044 (IK) and ETT No 239/2000 (LR).

Intervenous immunoglobulin for treatment of gastro-intestinal haemorrhage in dermatomyositis

Polyomysitis (PM) and dermatomyositis (DM) are systemic inflammatory disorders affecting skeletal muscles and other organs, especially the digestive tract. Oesophageal motor disturbances are common, occurring in as many as 25–60% of patients with PM/DM. Gastrointestinal disease is less recognised in PM/DM, though it may be responsible for life threatening complications—for example, dramatic haemorrhage, perforation, pseudo-obstruction, and pneumatosis cystoides intestinalis, and spontaneous abdominal haematoma. We recently observed a new case, which is of particular interest. The patient who had PM refractory to steroids and both gastrointestinal haemorrhage related to vasculitis and oesophageal impairment due to DM experienced a rapid and complete resolution of all clinical manifestations after interavenous immunoglobulin treatment was started.

An 18 year old man had DM evolving from March 1999. The diagnosis of DM was made by the Bohan and Peter criteria: (a) symmetrical muscle weakness. Muscle power was gauged for eight proximal muscles (neck flexors, trapezius, deltoid, biceps, psosas, maximus and medius gluteus, and quadriceps) by a modification of the British Medical Research Council Grading system, with grades ranging in a theoretical maximum score of 88 points. Muscle power of the patient was 73 points; (b) increased serum muscle enzymes—that is, creatine kinase (CK) 170 U/l (normal 5–130) and aldolase 7.2 U/l (normal 0.5–3.1); (c) myopathic changes on electromyography; (d) muscle damage on histological examination; and (e) characteristic dermatological manifestations—that is, heliotrope rash, periungual erythema, and poikiloderma.

Autoantibody screen was positive for anti-nuclear antibodies (ANA) with a value of 1/1000. Investigations, including pulmonary function tests, computed tomography scan of the chest, and endoscopy of the upper gastrointestinal tract all reported negative results. The patient was treated with immunosuppressive therapy, but the haemorrhage persisted. In addition, severe anaemia of unknown origin was observed.

On October 23, 2001, the patient was transferred to our hospital with new onset haematemesis. The total blood loss was estimated at 700 ml. The patient was haemodynamically stable. Initial laboratory examinations revealed haemoglobin 6.3 g/dl, white blood cell count 7700/mm³, platelet count 180 000/mm³, anti-nuclear antibody (ANA) titre 1/1000, anti-Sm antibody titre 1/160, anticyclic citrullinated peptide antibody titre 1/32, antinuclear antibody titre 1/1000, antiphospholipid antibodies titre 1/20, and dsDNA antibody titre 1/20. Antithrombin III activity was 71%, protein C 100%, and protein S 100%. Fibrinogen level was 195 mg/dl, D-dimer 169 µg/ml, prothrombin time 12.9 s, and activated partial thromboplastin time 37.8 s.

A barium swallow performed on the day of admission showed no abnormality. The patient was treated with fresh frozen plasma transfusions and packed red blood cell transfusions, however, the haemorrhage continued. After 72 hours, the haemoglobin level fell to 5.3 g/dl. After a total of 10 units of blood transfusions, the patient was referred for interventional treatment.

Informed consent was obtained from the patient and his family. The patient was transferred to our hospital with new onset haematemesis. The total blood loss was estimated at 700 ml. The patient was haemodynamically stable. Initial laboratory examinations revealed haemoglobin 6.3 g/dl, white blood cell count 7700/mm³, platelet count 180 000/mm³, anti-nuclear antibody (ANA) titre 1/1000, anti-Sm antibody titre 1/160, anticyclic citrullinated peptide antibody titre 1/32, antinuclear antibody titre 1/1000, antiphospholipid antibodies titre 1/20, and dsDNA antibody titre 1/20. Antithrombin III activity was 71%, protein C 100%, and protein S 100%. Fibrinogen level was 195 mg/dl, D-dimer 169 µg/ml, prothrombin time 12.9 s, and activated partial thromboplastin time 37.8 s.

A barium swallow performed on the day of admission showed no abnormality. The patient was treated with fresh frozen plasma transfusions and packed red blood cell transfusions, however, the haemorrhage continued. After 72 hours, the haemoglobin level fell to 5.3 g/dl. After a total of 10 units of blood transfusions, the patient was referred for interventional treatment.

Informed consent was obtained from the patient and his family. The patient was transferred to our hospital with new onset haematemesis. The total blood loss was estimated at 700 ml. The patient was haemodynamically stable. Initial laboratory examinations revealed haemoglobin 6.3 g/dl, white blood cell count 7700/mm³, platelet count 180 000/mm³, anti-nuclear antibody (ANA) titre 1/1000, anti-Sm antibody titre 1/160, anticyclic citrullinated peptide antibody titre 1/32, antinuclear antibody titre 1/1000, antiphospholipid antibodies titre 1/20, and dsDNA antibody titre 1/20. Antithrombin III activity was 71%, protein C 100%, and protein S 100%. Fibrinogen level was 195 mg/dl, D-dimer 169 µg/ml, prothrombin time 12.9 s, and activated partial thromboplastin time 37.8 s.

A barium swallow performed on the day of admission showed no abnormality. The patient was treated with fresh frozen plasma transfusions and packed red blood cell transfusions, however, the haemorrhage continued. After 72 hours, the haemoglobin level fell to 5.3 g/dl. After a total of 10 units of blood transfusions, the patient was referred for interventional treatment.
the lungs, echocardiography, and abdominal ultrasound were normal. Treatment with prednisone was started at a dose of 1 mg/kg daily. As both the clinical and biochemical status continued to deteriorate gradually, the steroid regimen was increased to a dose of 1.5 mg/kg daily from October 1999.

In July 1999 the patient presented with a two week history of dysphagia and melaena evolving from one day. On admission, his general condition was poor and abdominal palpation was tender. Physical examination also showed cutaneous manifestations of DM and muscle weakness affecting both arms and legs. Muscle power of the patient was 65 points. Laboratory findings were as follows: creatinine 108 µmol/l, urea 5.0 mmol/l, C reactive protein 30 mg/l, haemoglobin 6.6 mmol/l, mean corpuscular volume 90 fl, reticulocytes 150 × 10⁹/l, white blood cell count 10 × 10⁹/l, platelet count 490 × 10⁹/l, CK 3000 U/l, and aldolase 13.5 U/l. Findings of renal and liver tests, total protein, and albumin levels were normal. Autoantibody screening was positive for ANA >1:1000 with a speckled pattern; other tests, particularly for antinuclear factor, antineutrophil cytoplasmic antibodies, anti-cardiolipin and antiphospholipid antibodies, lupus-like anticoagulant, antineutrophil cytoplasmic antibodies, and cryoglobulin, were negative. Oesophageal manometry showed decreased peristalsis in the upper third of the oesophageal body and normal pressure in both upper and lower oesophageal sphincters. Gastroscopy demonstrated multiple small ulcerations affecting the stomach and the duodenum, with histology showing vascularitis of the small sized vessels.

A diagnosis of gastrointestinal haemorrhage related to vasculitis and oesophageal impairment due to DM was made. The patient was given intravenous immunoglobulin at a dose of 1 g/kg for two consecutive days monthly for six months. Prednisone was simultaneously decreased gradually to 5 mg every 15 days. The patient had no gastrointestinal haemorrhage recurrence, swallowing disorders and muscle strength improved rapidly, and the dermatological signs cleared.

In November 1999 methotrexate treatment was started at a dose of 30 mg weekly. At one year follow up, the patient remains free of digestive, cutaneous, and muscle symptoms with methotrexate at a dose of 30 mg weekly and 12 mg prednisone daily.

Esophageal motor abnormalities predominate in patients with PM/DM and have been extensively described, involvement of the gastrointestinal tract is considered to be less common.1 2 In a review of 96 patients with DM, Downey et al found that only four patients had gastrointestinal manifestations.3 Our findings confirm that gastrointestinal impairment is a major cause of morbidity in PM/DM, as our patient presented with life threatening gastrointestinal haemorrhage. A diagnosis of gastrointestinal vasculitis related to DM could reasonably be made for our patient because the onset of DM clinical deterioration and gastrointestinal haemorrhage is consistent and the search for other causes of vasculitis (notably systemic vasculitides or other connective tissue disorders) proved negative.

Our report further highlights the importance of recognising gastrointestinal complications at an early stage in PM/DM, resulting in accurate diagnosis and management, and therefore decreasing both morbidity and mortality. The pathological mechanisms of gastrointestinal involvement are still not clearly understood in PM/DM, though it may be related to vasculitis of small sized vessels, leading to ischaemia, haemorrhage, and perforation of the gastrointestinal wall.3 4 Moreover, the present case is original, as our patient with DM and life threatening digestive impairment received intravenous immunoglobulin treatment, which prevented gastrointestinal haemorrhage recurring and produced dramatic and rapid remission of swallowing disorders. Several authors have also mentioned a favourable outcome with intravenous immunoglobulin treatment in patients with systemic vasculitis—for example, Churg-Strauss vasculitis, microscopic polyangiitis, and lupus erythematosus.5 6 7 In this instance, a limitation was the concomitant continuation of steroids during the entire period of intravenous immunoglobulin treatment, making it difficult to be certain that the patient’s clinical improvement was only attributable to intravenous immunoglobulin treatment. However, the improvement of all gastrointestinal symptoms may reasonably be related to intravenous immunoglobulin treatment in our patient with DM because the gastrointestinal manifestations deteriorated persistently despite high doses of prednisone as a single treatment. The beneficial effect of the accompanying methotrexate therapy may also be excluded, as this later drug was started at the five month follow up of the patient.

Finally, our findings indicate that intravenous immunoglobulin should be considered the best treatment in both gastrointestinal haemorrhage related to vasculitis and oesophageal dysfunction due to steroid refractory DM, such a treatment offering the advantages of efficacy and good tolerance. However, no definite conclusion can be drawn and further controlled trials with a large number of patients with PM/DM are required to establish optimal doses and effective management.

Sjögren’s syndrome: an unusual cause of Bell’s palsy

The most common form of facial paralysis is idiopathic—that is, Bell’s palsy. Sjögren’s syndrome (SS), a chronic inflammatory disorder characterised by lymphocytic infiltration of exocrine glands resulting in the so called “sicca complex”, is a rare secondary cause of this self limiting illness. Primary SS includes mostly peripheral, and to a lesser extent central, autonomic neuropathy and central nervous system involvement.1 A patient with unilateral facial palsy, autoimmune hypothyroidism, and Sjögren’s syndrome is reported.

A 41 year old woman developed right sided facial numbness, described as “dentist anaesthesia for tooth extraction”. One day later she had a reduced sense of taste and right facial weakness. General physical examination was not remarkable. Neurological examination showed anisocoria, peripheral right sided facial paresis, reduced sense of taste on the right half of the tongue, and dysaesthesia in the right side of the second segment of the right trigeminal nerve.

Although the erythrocyte sedimentation rate (ESR) was 30 mm/1st h, routine laboratory investigations were normal. Complete blood count, including IgG, IgM and IgA, was normal. Magnetic resonance imaging (MRI) of the brain showed no abnormalities. Nerve conduction studies showed peripheral facial paresis. She recovered spontaneously from her symptoms within several days, during follow up the raised ESR persisted.

Review of her medical history uncovered complaints of burning eyes and dry mouth, slight weight gain, and cold intolerance. There was no history of arthritis or Raynaud’s phenomenon. She denied using any drugs previously. A review of her ocular history revealed a slight right corneal punctuate disorder. Further investigation, with negative tests for antinuclear factor/anti-nDNA antibodies/ rheumatoid factor and RNP/SS-B/Sm antibodies. Rose-Bengal staining showed corneal punctate lesions (van Bjiertvedl score 6). Lower labial biopsy showed histopathological findings matching the diagnosis of SS with a
Antitrypsin phenotypic variability is not associated with ANCA in southern Chinese

1. Antitrypsin (α1AT) is a 52 kDa protein encoded by a gene locus Pi on chromosomal segment 1q42.1. It is a natural inhibitor of protease 3 (PR3), a neutrophil granular protein and a major autoantigen of antineutrophil cytoplasmic antibody (ANCA). The function of α1AT is in turn restricted by myeloperoxidase (MPO), another autoantigen of ANCA. The interplay between the enzymes, inhibitors, and the autoantibodies is implicated in the dynamics of the vasculitic process, resulting in a whole spectrum of clinical conditions ranging from systemic granulomatous diseases to kidney limited glomerulonephritis. There have been reports of the correlation of specific α1AT alleles, notably PiZ, with ANCA. These were largely studies of white subjects, which may not necessarily be extrapolated to all populations. α1AT variant phenotypes may have predisposition to PR3-ANCA, but the same association may not exist for MPO-ANCA. In populations with a low prevalence of α1AT variant phenotypes, the pattern of ANCA could differ from that in white subjects where such variants prevail. We set out therefore to establish the distribution of α1AT in patients with the two main forms of ANCA (anti-PR3 positive and anti-MPO positive). Blood samples of patients with vasculitis received at the immunology section of the Department of Pathology, Department of Medicine, and Department of Rheumatology, King’s College Hospital, were tested for ANCA by indirect immunofluorescence, followed by enzyme linked immunosorbent assays (ELISA) for antineutrophil cytoplasmic antibody (ANCA) — PR3 or MPO.

Table 1  α1AT phenotypes in ANCA* (anti-PR3* or anti-MPO*) positive patients

<table>
<thead>
<tr>
<th>Phenoecytes</th>
<th>All ANCA+</th>
<th>Anti-PR3+</th>
<th>Anti-MPO+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Homozygous M</td>
<td>150(100)</td>
<td>130(100)</td>
<td>20(14)</td>
</tr>
<tr>
<td>M1 M1</td>
<td>99(63)</td>
<td>95(62)</td>
<td>4(3)</td>
</tr>
<tr>
<td>M2 M2</td>
<td>91(58)</td>
<td>88(59)</td>
<td>2(1)</td>
</tr>
<tr>
<td>M3 M3</td>
<td>73(46)</td>
<td>70(45)</td>
<td>1(1)</td>
</tr>
<tr>
<td>M4 M4</td>
<td>62(39)</td>
<td>59(38)</td>
<td>0(0)</td>
</tr>
<tr>
<td>Heterozygous M</td>
<td>17(11)</td>
<td>15(10)</td>
<td>1(1)</td>
</tr>
<tr>
<td>M1 M2</td>
<td>48(31)</td>
<td>45(30)</td>
<td>0(0)</td>
</tr>
<tr>
<td>M1 M3</td>
<td>33(21)</td>
<td>30(20)</td>
<td>2(1)</td>
</tr>
<tr>
<td>M2 M3</td>
<td>21(14)</td>
<td>19(12)</td>
<td>0(0)</td>
</tr>
<tr>
<td>Other heterozygous</td>
<td>0(0)</td>
<td>0(0)</td>
<td>0(0)</td>
</tr>
<tr>
<td>M1 S</td>
<td>0(0)</td>
<td>0(0)</td>
<td>0(0)</td>
</tr>
<tr>
<td>M2 S</td>
<td>0(0)</td>
<td>0(0)</td>
<td>0(0)</td>
</tr>
<tr>
<td>M1 other</td>
<td>0(0)</td>
<td>0(0)</td>
<td>0(0)</td>
</tr>
<tr>
<td>M2 other</td>
<td>0(0)</td>
<td>0(0)</td>
<td>0(0)</td>
</tr>
<tr>
<td>Total</td>
<td>170(100)</td>
<td>150(100)</td>
<td>20(14)</td>
</tr>
</tbody>
</table>

*ANCA = antineutrophil cytoplasmic antibody; PR3 = protease 3; MPO = myeloperoxidase.

www.annrheumdis.com
associated diseases in southern Chinese among whom anti-MPO predominated.


A case of cholesterol embolism with ANCA treated with corticosteroid and cyclophosphamide

We report a case of a patient with cholesterol embolism who showed positive for both myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA) and proteinase 3 antineutrophil cytoplasmic antibody (PR3-ANCA) and who was treated with prednisolone (PSL) and cyclophosphamide.

A 50 year old man underwent cardiac catheterisation for back pain. The examination disclosed 90% stenosis of the right coronary artery and a saccular aneurysm in the thoracic aorta. The patient underwent percutaneous transluminal coronary angioplasty and the aneurysm was wrapped with an artificial blood vessel. Postoperatively, the patient had a fever, pleural effusion, abdominal pain, and increased white blood cell (WBC) count. C reactive protein (CRP), and serum creatinine levels of blood and pleural exudate were negative. PSL 15 mg/day was started. However, acute progression of renal failure required haemodialysis.

The patient was transferred to our hospital. Physical examination showed a temperature of 38.0°C and blood pressure of 178/98 mmHg. Cyanosis was noted in both heels and all toes with necrosis and ulcers at the tips of the fifth toes. He had an increased erythrocyte sedimentation rate (ESR) of 82 mm/1st h. Anaemia was noted with a red blood cell count of 2500×10⁹/l, while the patient’s WBC count was high at 12×10⁹/l. His platelet count (304×10⁹/l) was within the normal range. Biochemistry showed high levels of blood urea nitrogen (10.0 mmol/l of urea), creatinine (710 µmol/l), and CRP (11.3 mg/l). Complements components were within normal ranges. PR3-ANCA and MPO-ANCA were high at 82E and 29E, respectively. After admission to hospital, circulatory disturbance in his toes worsened. A diagnosis of ANCA associated vasculitis was made based on systemic inflammatory findings and high levels of WBC, CRP, PR3-ANCA, and MPO-ANCA. High dose steroid treatment was started. Biopsies of the right heel skin and thigh quadriceps showed cholesterol embolism (fig 1). However, PSL treatment was continued together with three courses of cyclophosphamide pulse treatment because of persistent fever and high ANCA values. The treatment reduced the fever and toe necrosis, and the ulcers improved. ANCA gradually decreased to normal. The PSL dosage was reduced to 15 mg/day and the patient was discharged.

Cholesterol embolism predominantly affects elderly men with a history of hypertension, atherosclerotic vascular diseases, and renal insufficiency at the time of diagnosis. At least 31% of patients had a preceding history of anticoagulant use or the antecedent performance of a vascular procedure affecting the arterial circulation. The presence of these cholesterol embolisms within the vascular lumen triggers a characterised localised inflammatory and endothelial vascular reaction. The inflammatory changes resulting from cholesterol embolism may be responsible for many of the systemic manifestations such as fever, weight loss, myalgias, leucocytosis, eosinophilia, and a raised ESR. Thus cholesterol embolism is referred to as both vasculitis look-alikes and pseudovasculitis syndrome. The prognosis is poor, particularly in the presence of acute renal failure.

Three ANCA positive cases of cholesterol embolism have been described. Peat and Mathieson reported an ANCA positive patient with dyspnoea and haemoptysis after acute deterioration of renal function. Cyclophosphamide and PSL improved the symptoms, but cyclophosphamide was discontinued and the PSL dose was reduced because renal and skin biopsies showed cholesterol embolisms. Subsequently, the patient died of intractable cardiac failure.

Kaplan-Pavlovic et al reported two cases of renal failure with positive MPO-ANCA. The details are unknown for one patient. The other patient was treated with corticosteroid alone. This patient required haemodialysis and amputation of the toes. Although their treatment did not result in improvement of vasculitis, the combination of PSL and cyclophosphamide was effective in our patient with ANCA.

This result suggests that active treatment with corticosteroid and cyclophosphamide should be considered in ANCA positive cases of cholesterol embolism.

E MAISHIMA
Y YAMADA
M MUNE
Y YUKAWA

Third Department of Internal Medicine, Wakyayama Medical College, 811-1, Kimiidera, Wakyayama City, Wakyayama 641-0012, Japan

Correspondence to: Dr Maishima

www.amrheumdis.com

Figure 1 Skin biopsy specimen showing cholesterol embolism in arteries within subcutaneous tissues (haematoxylin and eosin, ×400).

HLA-DRB1*0301 and DQA1*0501 in RA

Auranofin is an oral gold preparation used in the treatment of rheumatoid arthritis (RA). During treatment, proteinuria has been reported in approximately 3% of patients.1 In a few cases in which renal biopsies were performed, a membranous nephropathy was shown to have developed.2

Several anti-inflammatory agents have been reported to induce renal manifestations or drug induced lupus reactions, or both, in patients with RA. In these subjects a genetic predisposition for HLA has been previously suggested.3 4

To determine whether similar genetic factors might be operative in auranofin induced nephropathy, we analysed the HLA-DRB1, DQA1, and DQB1 alleles using a polymerase chain reaction. Furthermore, we investigated if the renal side effects were associated with serological findings in accordance with systemic lupus erythematosus (SLE), thus indicating the development of a drug induced lupus reaction.

Six patients (three female, three male) who developed biopsy proven membranous nephropathy or significant proteinuria (>0.5 g/day) during treatment with auranofin are reported. All patients met the American College of Rheumatology criteria for RA.1 The median age before onset of auranofin treatment was 72 (52–83) years, 4/6 patients were rheumatoid factor positive and 2/5 patients were antinuclear antibody (ANA) positive. The median duration of auranofin treatment before the onset of proteinuria was 5 (4–10) months.

During auranofin treatment, two patients developed an increased ANA titre (1/200 and 1/1600) but no antibodies against anti-dsDNA, SSA/SSB, Sm, or RNP were detected. None of the patients developed an increased serum creatinine level. After withdrawal of auranofin, proteinuria decreased significantly or disappeared in all cases. Table 1 presents the HLA alleles.

A high frequency of the alleles associated with SLE—namely, DRB1*0301 (DR3), DQA1*0501, and DQB1*0201, was recorded in the patients developing membranous nephropathy or proteinuria during auranofin treatment. Of these, DRB1*0301 and DQA1*0501 occurred in 4/6 of the patients, and 5/6 patients carried at least one of these alleles.

The importance of DR3 or DQA1*0501 in drug induced renal manifestations has previously been suggested in patients with penicillamine and sodium aurothiomalate induced renal side effects.1 5 Also, in accordance with these findings, the DQA1*0501 and DRB1*0301 alleles have been recorded in a high frequency in patients developing sulfasalazine induced nephritis.6

In two cases the development of membranous nephropathy was accompanied by a simultaneous increase in the ANA titre, thus indicating development of a drug induced SLE reaction.7 However, both patients had previously presented some sign of an autoimmune reactivity pattern, which may confer a risk factor in the treatment with certain antirheumatic drugs in RA.

Simultaneous treatment with sulfasalazine had been given in two cases, but as the sulfasalazine treatment period was either limited, or lacked any time relation with the onset of proteinuria, it seems unlikely that the patients developed a drug reaction against sulfasalazine. Further arguments rejecting the possibility of a sulfasalazine induced drug reaction are the lack of anti-dsDNA antibodies and the rapid onset of proteinuria among the patients, thus contrasting with the findings reported in sulfasalazine induced SLE.7

The mechanism for induction of membranous nephropathy during auranofin treatment is unknown. Interestingly, it has been suggested that gold can bind to and alter major histocompatibility complex-peptide complexes,8 thus giving a possible explanation of both beneficial effects as well as side effects during treatment. Another possibility is that auranofin may alter the cytokine pattern towards an SLE-like phenotype and thus facilitate the development of SLE associated manifestations in genetically susceptible subjects. In accordance with this hypothesis, auranofin or other gold preparations have been reported to inhibit the production of interleukin 1 (IL1), tumour necrosis factor α, and IL2.9 10 The effects on IL10, a cytokine reported to be increased in drug induced lupus erythematosus, is unknown, however.

In conclusion, the data suggest that SLE related HLA alleles, with special focus on DRB1*0301 and DQA1*0501, may predispose to development of renal side effects or drug induced lupus reactions during treatment with auranofin, as also previously recorded during treatment with other antirheumatic agents. Development of drug induced SLE, here reported for the first time, may occur during auranofin treatment.


Table 1 HLA DRB1*, DQA1*, and DQB1* alleles in patients with development of renal manifestations during auranofin treatment

<table>
<thead>
<tr>
<th>Patient</th>
<th>DRB1*</th>
<th>DQA1*</th>
<th>DQB1*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0301</td>
<td>0801</td>
<td>0501</td>
</tr>
<tr>
<td>2</td>
<td>0101</td>
<td>0301</td>
<td>0101</td>
</tr>
<tr>
<td>3</td>
<td>0101</td>
<td>0301</td>
<td>0101</td>
</tr>
<tr>
<td>4</td>
<td>0101</td>
<td>0301</td>
<td>0101</td>
</tr>
<tr>
<td>5*</td>
<td>0401</td>
<td>1301</td>
<td>0303</td>
</tr>
<tr>
<td>6*</td>
<td>0101</td>
<td>0301</td>
<td>0102</td>
</tr>
</tbody>
</table>

*No renal biopsy was performed in these patients.